💊 Sanofi's new global scholarship programme launches; J&J's HIV vaccine will never launch; India's CDSCO says Maiden Pharma drugs are of low quality

#258 | A new test for early detection of Alzheimer's; Avoiding routine vaccines can lead to Alzheimer's, and dementia too

Hello, and welcome back to The Kable for a more sedate affair today.

Ahead of an activist-impelled break-up, Bayer is piling on the pounds with an acquisition of its digital imaging partner of the past 2+ years, Blackford Analysis. Financial terms for the deal haven’t been disclosed yet.

In a new twist to India’s ongoing QC affair, Maiden Pharma, the company in the eye of the storm over child deaths in The Gambia, found five samples of its cough syrup in a list of low-quality drugs prepared by the country’s drug regulator. Other companies to be included in the December edition of sample testing outcomes include GSK and Cipla.

Yet another feather in Rwanda’s medical hat, this time thanks to a 5-year partnership with Belgium’s Institute of Tropical Medicine aimed at bolstering lab testing capabilities for TB.

Did you think bird flu had disappeared just because we haven't mentioned it in a while? Well, think again. Coz bird flu ain’t flying away anytime soon. PAHO has just issued an alert over outbreaks in 10 countries in the Americas.

And finally, in excellent news, Sanofi has launched a global scholarship programme for students from underrepresented communities pursuing careers in healthcare. With a €50 million initial investment.